Mechanisms of drugs in the treatment of type 2 diabetes mellitus

• Published in: Chinese medical journal Vol. 136; no. 4; pp. 394 - 396
• Main Authors: Yang, Tao, Wang, Hongmei, Li, Caili, Duan, Haogang
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins Ovid Technologies 20.02.2023; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Blood pressure; Clinical trials; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Drug therapy; Enzymes; Fatty acids; Glucagon; Glucose; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents - therapeutic use; Insulin resistance; Metabolism; Mortality; Peptides; Proteins; R&D; Research & development; China
• ISSN: 2542-5641; 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000002356

See PDF] Dipeptidyl peptidase-4 (DPP-4) inhibitors are known to increase insulin levels, lower blood glucose, and protect the functioning of pancreatic islet cells, which demonstrate a significant role in the treatment of type 2 diabetes. [20,21] The AMP-activated kinase (AMPK) acts as an energy-sensing enzyme that is activated when cellular energy levels are low and stimulates skeletal muscle uptake of glucose, fat, and other tissue oxidized fatty acids, and reduces hepatic glucose production. References 1.Chai, SWu, SXin, SYuan, NSun, JZhang, X. Negative association of time in range and urinary albumin excretion rate in patients with type 2 diabetes mellitus: a retrospective study of inpatients. Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials.